PURA Finalizes CBD Infused Liquid Sugar Formula With Alkame Holdings
May 11 2021 - 11:55AM
InvestorsHub NewsWire
DALLAS, TX --
May 11, 2021 -- InvestorsHub NewsWIre -- Puration, Inc. (USOTC:
PURA) and Alkame Holdings Inc. (USOTC:
ALKM) today announced finalizing a formula for a new CBD
infused liquid sugar and plans to soon begin
production.
In December
2020, PURA and ALKM announced plans to produce and test market a
CBD infused liquid sugar, a CBD infused pet food supplement and a
CBD sexual wellness flavored
lubricant.
ALKM currently
bottles PURA's EVERx CBD Sports Water. As part of a growing
partnership, PURA has recently acquired
a five percent
stake in ALKM. In
conjunction with that growing partnership, ALKM and PURA plan to
pilot the production of multiple new CBD infused consumer
products.
PURA owns a
license to a U.S. Patented cannabis extraction process backed by
extensive university medical research. The license, issued by NCM
Biotech, is exclusive for beverages, edibles and cosmetics among
other uses. NCM Biotech is focused on medical research and Puration
has access to that research.
PURA and ALKM
plan to soon announce beginning production on the new CBD infused
liquid sugar in addition to updates on progress with the additional
new products.
For more
information on Puration, visit http://www.purationinc.com
For more
information, visit www.alkameholdingsinc.com.
CONTACT:
Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
+1 (800)
861-1350
Disclaimer/Safe
Harbor: This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that Alkame will achieve significant sales, the failure
to meet schedule or performance requirements of the Company's
contracts, the Company's liquidity position, the Company's ability
to obtain new contracts, the emergence of competitors with greater
financial resources and the impact of competitive pricing. In the
light of these uncertainties, the forward-looking events referred
to in this release might not occur. These statements have not been
evaluated by the Food and Drug Administration. These products are
not intended to diagnose, treat, cure, or prevent any
disease.
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Apr 2023 to Apr 2024